HIV vaccines: New frontiers in vaccine development

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 500-511

  Duerr, Ann ^a,b   Wasserheit, Judith N ^a   Corey, Lawrence ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AVX 101; DNA; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 15; LIVE VACCINE; NEF PROTEIN; POL PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; VIRUS GENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; DISEASE VECTORS; DNA, VIRAL; HIV; HIV INFECTIONS; HUMANS;

EID: 33746598200     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505979     Document Type: Review

References (68)

1. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-9.
2. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59.
3. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G. Molecular epidemiology of HIV. Indian J Med Res 2005; 121:333-44.
4. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
5. Lynch JA, deSouza M, Robb MD, et al. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998; 178: 1040-6.
6. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 1997;94:1396-401.
7. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002; 2:461-71.
8. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 2002; 76:8757-68.
9. van der Groen G, Nyambi PN, Beirnaert E, et al. Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S211-21.
10. Ferrari G, Kostyu DD, Cox J, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res Hum Retroviruses 2000; 16:1433-43.
11. Fukada K, Tomiyama H, Wasi C, et al. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS 2002; 16:701-11.
12. Buseyne F, Chaix ML, Fleury B, et al. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology 1998; 250:316-24.
13. + cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses 1998; 14: 925-37.
14. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
15. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-18.
16. Conley AJ, Kessler JA II, Boots LJ, et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996; 70:6751-8.
17. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992; 355:728-30.
18. Gilbert PB, Chiu YL, Allen M, et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 2003; 21: 2933-47.
19. de Bruyn G, Rossini AJ, Chiu YL, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 2004; 22:704-13.
20. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group protocol 022A. J Acquir Immune Defic Syndr 2002; 29: 254-61.
21. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1: the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340-8.
22. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77.
23. Graham BS, Mascola JR. Lessons from failure: preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 2005; 191:647-9.
24. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
25. Pitisutithum P. Efficacy of AIDSVAX B/E vaccines in injecting drug use [abstract 107]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunisitic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004: 115.
26. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004; 4:397-413.
27. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-12.
28. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV: back in the major leagues? Curr Opin Immunol 2002; 14:495-502.
29. Ferrantelli F, Rasmussen RA, Buckley KA, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004; 189:2167-73.
30. Ferrantelli F, Kitabwalla M, Rasmussen RA, et al. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies: implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2004; 189:71-4.
31. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-6.
32. Seth A, Ourmanov I, Schmitz JE, et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-pol primes for an anamnestic gag-specific cytoloxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 2000; 74:2502-9.
33. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
34. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
35. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
36. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
37. Jenner E. An inquiry into the causes and effects of the variolae vaccinae. London: Low, 1798.
38. Learmont J, Cook L, Dunckley H, Sullivan JS. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruses 1995; 11:1.
39. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-7.
40. Nathanson N, Langmuir AD. The cutter incident: poliomyelitis following formalde. Am J Hyg 1963; 78:29-60.
41. Hanke T, Samuel RV, Blanchard TJ, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-32.
42. Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164:4968-78.
43. Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5:526-34.
44. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
45. Seaman MS, Xu L, Beaudry K, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005; 79:2956-63.
46. Graham B. Update on VRC clinical trials of multi-clade DNA and rAd5 vaccines [abstract X8 041]. In: Keystone symposia HIV pathogenesis/HIV vaccines (Banff, Alberta, Canada) 2005; 21.
47. + cytotoxic T lymphocytes. Science 1991; 252: 440-3.
48. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337:567-72.
49. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316:673-6.
50. Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004; 3:589-97.
51. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188:217-32.
52. Hel Z, Tsai WP, Thornton A, et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J Immunol 2001; 167:7180-91.
53. + T cell responses. J Immunol 2002; 169:4778-87.
54. Joako W, Omosa G, Bhatt K, et al. Safety and immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya [abstract 54]. In: Program and abstracts of AIDS Vaccine 2004 (Lausanne, Switzerland). Switzerland 2004:33.
55. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with rgp120. J Infect Dis 2001; 183:563-70.
56. Belshe RB, Gorse GJ, Mulligan MJ, et al.; NIAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407-15.
57. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004; 3: S75-88.
58. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305-13.
59. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-72.
60. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005; 79:6516-22.
61. Letvin NL, Huang Y, Chakrabarti BK, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490-7.
62. Isaacs R. Evaluating the efficacy of the Merck adenovirus serotype 5-based trivalent MRKAd5 gag/pol/nef vaccine [abstract 42]. In: Program and abstracts of AIDS Vaccine 2005 (Montreal, Quebec, Canada). 2005:11.
63. Graham B. Safety and immunogenicity of multiclade HIV-1 recombinant adenovirus vaccine boost in prior recipients of a multiclade HIV-1 DNA vaccine [abstract 15]. In: Program and abstracts of AIDS Vaccines 2005 (Montreal, Quebec, Canada) 2005:9.
64. Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005; 79:771-9.
65. Morgan C, Bailer R, Metch B, et al. International seroprevalence of neutralizing antibodies against adenovirus [abstract 301P]. In: Program and abstracts of AIDS Vaccines 2005 (Montreal, Quebec, Canada). 2005.
66. Cohen J. HIV/AIDS: hedged bet: an unusual AIDS vaccine trial. Science 2005; 309:1003.
67. AIDS Vaccine Bulletin. Volume 1, no. 1, January 2006. Available at: http://www.iavireport.org/. Accessed 1 March 2006.
68. The Pipeline Project. Available at: http://chi.ucsf.edu/vaccines/. Accessed 26 January 2006.